DiaMedica Issues Stock Option Grant – P&T Community

MINNEAPOLIS, Aug. 23, 2018 (GLOBE NEWSWIRE) — DiaMedica Therapeutics Inc. (the “Company“) (TSX VENTURE:DMA) (OTCQB:DMCAF), today announces it has issued 600,000 stock options to new employees and advisors of the Company.  The options were issued at $0.52 per share and have a ten-year term.

The options were granted under the Company’s Stock Option Plan and are part of the Company’s long term incentive/retention plan for employees and directors. The option issuance is subject to the approval of the TSX Venture Exchange.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica’s shares are listed on the TSX Venture Exchange under the trading symbol “DMA” and on the OTCQB under the trading symbol “DMCAF”. For more information, please visit www.diamedica.com. Follow us on social media – Twitter, LinkedIn.


Paul Papi
Vice President of Business Development
DiaMedica Therapeutics Inc.
Phone: (617) 899-5941

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.